Vascular Biogenics
Market Cap
US$58.5m
Last Updated
2020/07/04 23:59 UTC
Data Sources
Company Financials +
Executive Summary
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer.
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Flawless balance sheet and overvalued.
Share Price & News
How has Vascular Biogenics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VBLT's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.5%
VBLT
3.1%
US Biotechs
4.0%
US Market
1 Year Return
-6.1%
VBLT
24.3%
US Biotechs
4.9%
US Market
Return vs Industry: VBLT underperformed the US Biotechs industry which returned 24.2% over the past year.
Return vs Market: VBLT underperformed the US Market which returned 5% over the past year.
Shareholder returns
| VBLT | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.5% | 3.1% | 4.0% |
| 30 Day | -3.1% | 7.3% | 1.3% |
| 90 Day | 5.2% | 31.2% | 29.5% |
| 1 Year | -6.1%-6.1% | 25.5%24.3% | 7.2%4.9% |
| 3 Year | -72.9%-72.9% | 32.8%28.4% | 36.1%27.2% |
| 5 Year | -80.3%-80.3% | 0.04%-5.7% | 65.3%46.9% |
Price Volatility Vs. Market
How volatile is Vascular Biogenics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What Percentage Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares Do Insiders Own?1 month ago | Simply Wall St
Earnings Update: Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Are Boosting Their Estimates1 month ago | Simply Wall St
Vascular Biogenics (NASDAQ:VBLT) Is In A Good Position To Deliver On Growth PlansValuation
Is Vascular Biogenics undervalued compared to its fair value and its price relative to the market?
1.41x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VBLT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VBLT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VBLT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: VBLT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VBLT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VBLT is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Vascular Biogenics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
11.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VBLT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VBLT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VBLT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VBLT's revenue is expected to decline over the next 3 years (-3.3% per year).
High Growth Revenue: VBLT's revenue is forecast to decline over the next 3 years (-3.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VBLT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Vascular Biogenics performed over the past 5 years?
-3.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VBLT is currently unprofitable.
Growing Profit Margin: VBLT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VBLT is unprofitable, and losses have increased over the past 5 years at a rate of -3.3% per year.
Accelerating Growth: Unable to compare VBLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VBLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: VBLT has a negative Return on Equity (-65.62%), as it is currently unprofitable.
Next Steps
Financial Health
How is Vascular Biogenics's financial position?
Financial Position Analysis
Short Term Liabilities: VBLT's short term assets ($32.6M) exceed its short term liabilities ($7.9M).
Long Term Liabilities: VBLT's short term assets ($32.6M) exceed its long term liabilities ($3.7M).
Debt to Equity History and Analysis
Debt Level: VBLT is debt free.
Reducing Debt: VBLT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VBLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VBLT has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 0.9% each year.
Next Steps
Dividend
What is Vascular Biogenics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VBLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VBLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VBLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VBLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VBLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
14.5yrs
Average management tenure
CEO
Dror Harats (63yo)
20.5yrs
Tenure
US$3,070,000
Compensation
Prof. Dror Harats, MD, has been the Chief Executive Officer of Vascular Biogenics Ltd., since 2000. Prof. Harats founded VBL in 2000 based on many years of research in Atherosclerosis, Vascular Biology and ...
CEO Compensation Analysis
Compensation vs Market: Dror's total compensation ($USD893.19K) is above average for companies of similar size in the US market ($USD605.69K).
Compensation vs Earnings: Dror's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 20.5yrs | US$3.07m | 1.43% $838.4k | |
| CFO & Company Secretary | 9.17yrs | US$1.47m | 0.50% $292.3k | |
| Vice President of Business Operations | 6.5yrs | US$1.29m | 0.32% $189.0k | |
| Vice President of Research & Operations | 14.5yrs | US$1.50m | 0.36% $212.1k | |
| Vice President of Drug Development & Regulatory Affairs | 14.5yrs | US$1.25m | 0.26% $153.7k | |
| General Counsel | 20.5yrs | no data | 0.099% $58.1k | |
| Managing Director of Financial Communications | no data | no data | no data | |
| Medical Director | 12.5yrs | US$982.00k | no data |
14.5yrs
Average Tenure
57yo
Average Age
Experienced Management: VBLT's management team is seasoned and experienced (14.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 20.5yrs | US$3.07m | 1.43% $838.4k | |
| Independent Non-Executive Director | 10.33yrs | no data | 0.080% $46.9k | |
| Independent Non-Executive Director | 2.5yrs | no data | 0.078% $45.8k | |
| Independent Non-Executive Director | 12.92yrs | no data | 0.18% $105.8k | |
| Independent Non-Executive Chairman | 13.5yrs | no data | 0.089% $52.3k | |
| Independent Non-Executive Director & Head of Scientific Advisory Board | 0.42yr | no data | 0.078% $45.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
11.6yrs
Average Tenure
66.5yo
Average Age
Experienced Board: VBLT's board of directors are seasoned and experienced ( 11.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VBLT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.5%.
Top Shareholders
Company Information
Vascular Biogenics Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Vascular Biogenics Ltd.
- Ticker: VBLT
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$58.468m
- Shares outstanding: 47.90m
- Website: https://www.vblrx.com
Number of Employees
Location
- Vascular Biogenics Ltd.
- 8 HaSatat Street
- Modi’in
- 78106
- Israel
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| VBLT | NasdaqGM (Nasdaq Global Market) | Yes | Ordinary Shares | US | USD | Oct 2014 |
Biography
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi’in, Israel.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/04 23:59 |
| End of Day Share Price | 2020/07/02 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.